Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9725MR)

This product GTTS-WQ9725MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9725MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14274MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ9387MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ10446MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ5200MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ8783MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ5611MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ13279MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ11999MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-121
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW